title: Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats.
abstract: The objective of this multiple-dose toxicity study was to assess the toxicological potential of two tripeptides, L-valyl-L-prolyl-L-proline (VPP) and L-isoleucyl-L-prolyl-L-proline (IPP), when administered once daily for 91 consecutive days to rats. The test article, powdered casein hydrolysate (CH) known to contain 0.6% VPP plus IPP, was prepared using Aspergillus oryzae protease. Prior to administration to the rats by oral gavage, the test article was suspended in sterile water. Groups of 12 male and 12 female Charles River rats were administered once daily doses of 0, 40, 200, or 1000 mg of CH (0, 0.2, 1.2, or 6 mg VPP plus IPP/kg body weight [BW]). Antemortem evaluative parameters included gross observations of behavior and clinical signs; food consumption and body weight gains; ophthalmologic examinations; clinical pathology (hematology, clinical chemistry); and urinalysis. Postmortem parameters included determination of absolute and relative (to fasting body weight) organ weights and histopathological evaluation of approximately 50 organs and tissues from each animal. All rats survived until the scheduled termination of the study and no treatment-related clinical signs were observed. Food consumption was unaffected by administration of CH. All animals gained weight and there were no statistical differences between groups with respect to weight gains. There were no meaningful changes in hematological or coagulation parameters. Mid- and high-dose males (but not females) had slightly (< 2%) increased mean serum chloride concentrations, but because the difference was so small and it was observed in only one sex, the authors considered its association with CH administration to be doubtful. Urinalysis revealed the occasional presence of crystals, leukocytes, and epithelial cells in animals from all experimental groups. Similarly, ophthalmic changes (lenticular clouding) were observed in both control and dosed animals. Mean relative (to body weight) kidney weight was decreased by 8% in low-dose males and mean relative uterus weight was elevated 46% in low-dose females. Absolute organ weights were not affected. Only naturally occurring microscopic changes were observed in all groups and none could be attributed to CH administration. It was concluded that, under the conditions of these experiments, the maximally tolerated dose (MTD) and the no-observable-effect level (NOEL) for powdered CH administered once daily for 13 weeks was greater than 1000 mg/kg BW/day or greater than 6 mg of VPP plus IPP/kg BW/day. There was no evidence of target organ toxicity associated with administration of the tripeptides. This corresponds to an margin of safety (MOS) of 60 based upon current thinking regarding incorporation in food.
authors.affiliation: Food Research Laboratory, Calpis Co., Ltd., 11-10, 5-chome, Fuchinobe, Sagamihara, Kanagawa, Japan. seiichi.mizuno@calpis.co.jp
authors.forename: Seiichi
authors.initials: S
authors.lastname: Mizuno
authors.forename: John H
authors.initials: JH
authors.lastname: Mennear
authors.forename: Keiichi
authors.initials: K
authors.lastname: Matsuura
authors.forename: Bruce K
authors.initials: BK
authors.lastname: Bernard
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002364:Caseins / Q000008:administration & dosage / Q000737:chemistry; D002386:Cataract / Q000175:diagnosis; D002712:Chlorides / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005260:Female; D006403:Hematologic Tests; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D009929:Organ Size / Q000187:drug effects; D011208:Powders; D051381:Rats; D017207:Rats, Sprague-Dawley; D012737:Sex Factors; D013997:Time Factors; D018675:Toxicity Tests / Q000379:methods; D014558:Urobilinogen / Q000652:urine; D014599:Uterus / Q000187:drug effects / Q000473:pathology; D015430:Weight Gain / Q000187:drug effects
chemical_list: D002364:Caseins; D002712:Chlorides; D009842:Oligopeptides; D011208:Powders; C489032:isoleucyl-prolyl-proline; D014558:Urobilinogen; C489031:valyl-prolyl-proline; C475729:casein hydrolysate